-
Je něco špatně v tomto záznamu ?
Safety and efficacy of intrathecal antibodies to Nogo-A in patients with acute cervical spinal cord injury: a randomised, double-blind, multicentre, placebo-controlled, phase 2b trial
N. Weidner, R. Abel, D. Maier, K. Röhl, F. Röhrich, M. Baumberger, M. Hund-Georgiadis, M. Saur, J. Benito, K. Rehahn, M. Aach, A. Badke, J. Kriz, K. Barkovits, T. Killeen, L. Farner, M. Seif, M. Hubli, K. Marcus, MA. Maurer, B. Robert, R. Rupp,...
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, randomizované kontrolované studie, klinické zkoušky, fáze II, multicentrická studie
NLK
ProQuest Central
od 2002-05-01 do Před 2 měsíci
Nursing & Allied Health Database (ProQuest)
od 2002-05-01 do Před 2 měsíci
Health & Medicine (ProQuest)
od 2002-05-01 do Před 2 měsíci
Psychology Database (ProQuest)
od 2002-05-01 do Před 2 měsíci
- MeSH
- dospělí MeSH
- dvojitá slepá metoda MeSH
- krční mícha * zranění MeSH
- krční obratle MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- Nogo proteiny * MeSH
- poranění míchy * farmakoterapie MeSH
- senioři MeSH
- spinální injekce * MeSH
- výsledek terapie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky, fáze II MeSH
- multicentrická studie MeSH
- randomizované kontrolované studie MeSH
BACKGROUND: Spinal cord injury results in permanent neurological impairment and disability due to the absence of spontaneous regeneration. NG101, a recombinant human antibody, neutralises the neurite growth-inhibiting protein Nogo-A, promoting neural repair and motor recovery in animal models of spinal cord injury. We aimed to evaluate the efficacy of intrathecal NG101 on recovery in patients with acute cervical traumatic spinal cord injury. METHODS: This randomised, double-blind, placebo-controlled phase 2b clinical trial was done at 13 hospitals in the Czech Republic, Germany, Spain, and Switzerland. Patients aged 18-70 years with acute, complete or incomplete cervical spinal cord injury (neurological level of injury C1-C8) within 4-28 days of injury were eligible for inclusion. Participants were initially randomly assigned 1:1 to intrathecal treatment with 45 mg NG101 or placebo (phosphate-buffered saline); 18 months into the study, the ratio was adjusted to 3:1 to achieve a final distribution of 2:1 to improve enrolment and drug exposure. Randomisation was done using a centralised, computer-based randomisation system and was stratified according to nine distinct outcome categories with a validated upper extremity motor score (UEMS) prediction model based on clinical parameters at screening. Six intrathecal injections were administered every 5 days over 4 weeks, starting within 28 days of injury. Investigators, study personnel, and study participants were masked to treatment allocation. The primary outcome was change in UEMS at 6 months, analysed alongside safety in the full analysis set. The completed trial was registered at ClinicalTrials.gov, NCT03935321. FINDINGS: From May 20, 2019, to July 20, 2022, 463 patients with acute traumatic cervical spinal cord injury were screened, 334 were deemed ineligible and excluded, and 129 were randomly assigned to an intervention (80 patients in the NG101 group and 49 in the placebo group). The full analysis set comprised 78 patients from the NG101 group and 48 patients from the placebo group. 107 (85%) patients were male and 19 (15%) patients were female, with a median age of 51·5 years (IQR 30·0-60·0). Across all patients, the primary endpoint showed no significant difference between groups (with UEMS change at 6 months 1·37 [95% CI -1·44 to 4·18]; placebo group mean 19·20 [SD 11·78] at baseline and 30·91 [SD 15·49] at day 168; NG101 group mean 18·23 [SD 15·14] at baseline and 31·31 [19·54] at day 168). Treatment-related adverse events were similar between groups (nine in the NG101 group and six in the placebo group). 25 severe adverse events were reported: 18 in 11 (14%) patients in the NG101 group and seven in six (13%) patients in the placebo group. Although no treatment-related fatalities were reported in the NG101 group, one fatality not related to treatment occurred in the placebo group. Infections were the most common adverse event affecting 44 (92%) patients in the placebo group and 65 (83%) patients in the NG101 group. INTERPRETATION: NG101 did not improve UEMS in patients with acute spinal cord injury. Post-hoc subgroup analyses assessing UEMS and Spinal Cord Independence Measure of self-care in patients with motor-incomplete injury indicated potential beneficial effects that require investigation in future studies. FUNDING: EU program Horizon2020; Swiss State Secretariat for Education, Research and Innovation; Wings for Life; the Swiss Paraplegic Foundation; and the CeNeReg project of Wyss Zurich (University of Zurich and Eidgenössische Technische Hochschule Zurich).
BG Clinic Tübingen Tübingen Germany
Clinic for Paraplegia Klinikum Bayreuth GmbH Bayreuth Germany
Clinic of Neurorehabilitation and Paraplegiology REHAB Basel Basel Switzerland
Clinical Study Coordination Center University of Heidelberg Heidelberg Germany
Department of Spinal Cord Injuries BG University Hospital Bergmannsheil Bochum Germany
Epidemiology Biostatistics and Prevention Institute University of Zurich Switzerland
Fundacio Institut d'Investigacio en Ciencies de la Salut Germans Trias i Pujol Barcelona Spain
Institute for Regenerative Medicine University of Zurich Switzerland
International Collaboration on Repair Discoveries University of British Columbia Vancouver BC Canada
Medical Proteome Analysis Center for Proteindiagnostics Ruhr University Bochum Bochum Germany
Orthopädische Klinik Hessisch Lichtenau Germany
Spinal Cord Injuries Berufsgenossenschaftliche Unfallklinik Murnau Murnau Germany
Spinal Cord Injury Center Balgrist University Hospital University of Zurich Zurich Switzerland
Spinal Cord Injury Center Heidelberg University Hospital Heidelberg Germany
Swiss Paraplegic Centre Nottwil Switzerland
Treatment Centre for Spinal Cord Injuries Trauma Hospital Berlin Berlin Germany
Wellcome Centre for Human Neuroimaging Institute of Neurology University College London London UK
Wyss Zurich Translational Center University and ETH Zurich Zurich Switzerland
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25002848
- 003
- CZ-PrNML
- 005
- 20250206103913.0
- 007
- ta
- 008
- 250121s2025 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/S1474-4422(24)00447-2 $2 doi
- 035 __
- $a (PubMed)39706632
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Weidner, Norbert $u Spinal Cord Injury Center, Heidelberg University Hospital, Heidelberg, Germany. Electronic address: norbert.weidner@med.uni-heidelberg.de
- 245 10
- $a Safety and efficacy of intrathecal antibodies to Nogo-A in patients with acute cervical spinal cord injury: a randomised, double-blind, multicentre, placebo-controlled, phase 2b trial / $c N. Weidner, R. Abel, D. Maier, K. Röhl, F. Röhrich, M. Baumberger, M. Hund-Georgiadis, M. Saur, J. Benito, K. Rehahn, M. Aach, A. Badke, J. Kriz, K. Barkovits, T. Killeen, L. Farner, M. Seif, M. Hubli, K. Marcus, MA. Maurer, B. Robert, R. Rupp, PS. Scheuren, M. Schubert, C. Schuld, C. Sina, B. Steiner, T. Weis, A. Hug, M. Bolliger, N. Weiskopf, P. Freund, T. Hothorn, ME. Schwab, A. Curt, Nogo Inhibition in Spinal Cord Injury Study Group
- 520 9_
- $a BACKGROUND: Spinal cord injury results in permanent neurological impairment and disability due to the absence of spontaneous regeneration. NG101, a recombinant human antibody, neutralises the neurite growth-inhibiting protein Nogo-A, promoting neural repair and motor recovery in animal models of spinal cord injury. We aimed to evaluate the efficacy of intrathecal NG101 on recovery in patients with acute cervical traumatic spinal cord injury. METHODS: This randomised, double-blind, placebo-controlled phase 2b clinical trial was done at 13 hospitals in the Czech Republic, Germany, Spain, and Switzerland. Patients aged 18-70 years with acute, complete or incomplete cervical spinal cord injury (neurological level of injury C1-C8) within 4-28 days of injury were eligible for inclusion. Participants were initially randomly assigned 1:1 to intrathecal treatment with 45 mg NG101 or placebo (phosphate-buffered saline); 18 months into the study, the ratio was adjusted to 3:1 to achieve a final distribution of 2:1 to improve enrolment and drug exposure. Randomisation was done using a centralised, computer-based randomisation system and was stratified according to nine distinct outcome categories with a validated upper extremity motor score (UEMS) prediction model based on clinical parameters at screening. Six intrathecal injections were administered every 5 days over 4 weeks, starting within 28 days of injury. Investigators, study personnel, and study participants were masked to treatment allocation. The primary outcome was change in UEMS at 6 months, analysed alongside safety in the full analysis set. The completed trial was registered at ClinicalTrials.gov, NCT03935321. FINDINGS: From May 20, 2019, to July 20, 2022, 463 patients with acute traumatic cervical spinal cord injury were screened, 334 were deemed ineligible and excluded, and 129 were randomly assigned to an intervention (80 patients in the NG101 group and 49 in the placebo group). The full analysis set comprised 78 patients from the NG101 group and 48 patients from the placebo group. 107 (85%) patients were male and 19 (15%) patients were female, with a median age of 51·5 years (IQR 30·0-60·0). Across all patients, the primary endpoint showed no significant difference between groups (with UEMS change at 6 months 1·37 [95% CI -1·44 to 4·18]; placebo group mean 19·20 [SD 11·78] at baseline and 30·91 [SD 15·49] at day 168; NG101 group mean 18·23 [SD 15·14] at baseline and 31·31 [19·54] at day 168). Treatment-related adverse events were similar between groups (nine in the NG101 group and six in the placebo group). 25 severe adverse events were reported: 18 in 11 (14%) patients in the NG101 group and seven in six (13%) patients in the placebo group. Although no treatment-related fatalities were reported in the NG101 group, one fatality not related to treatment occurred in the placebo group. Infections were the most common adverse event affecting 44 (92%) patients in the placebo group and 65 (83%) patients in the NG101 group. INTERPRETATION: NG101 did not improve UEMS in patients with acute spinal cord injury. Post-hoc subgroup analyses assessing UEMS and Spinal Cord Independence Measure of self-care in patients with motor-incomplete injury indicated potential beneficial effects that require investigation in future studies. FUNDING: EU program Horizon2020; Swiss State Secretariat for Education, Research and Innovation; Wings for Life; the Swiss Paraplegic Foundation; and the CeNeReg project of Wyss Zurich (University of Zurich and Eidgenössische Technische Hochschule Zurich).
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a poranění míchy $x farmakoterapie $7 D013119
- 650 _2
- $a dvojitá slepá metoda $7 D004311
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a dospělí $7 D000328
- 650 12
- $a Nogo proteiny $7 D000070798
- 650 12
- $a spinální injekce $7 D007278
- 650 _2
- $a senioři $7 D000368
- 650 12
- $a krční mícha $x zranění $7 D066193
- 650 _2
- $a mladý dospělý $7 D055815
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a krční obratle $7 D002574
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 655 _2
- $a klinické zkoušky, fáze II $7 D017427
- 655 _2
- $a multicentrická studie $7 D016448
- 700 1_
- $a Abel, Rainer $u Clinic for Paraplegia, Klinikum Bayreuth GmbH, Bayreuth, Germany
- 700 1_
- $a Maier, Doris $u Spinal Cord Injuries, Berufsgenossenschaftliche Unfallklinik Murnau, Murnau, Germany
- 700 1_
- $a Röhl, Klaus $u BG Klinikum Bergmannstrost Halle gGmbH, Zentrum für Rückenmarkverletzte und Klinik für Orthopädie, Halle, Germany
- 700 1_
- $a Röhrich, Frank $u BG Klinikum Bergmannstrost Halle gGmbH, Zentrum für Rückenmarkverletzte und Klinik für Orthopädie, Halle, Germany
- 700 1_
- $a Baumberger, Michael $u Swiss Paraplegic Centre, Nottwil, Switzerland
- 700 1_
- $a Hund-Georgiadis, Margret $u Clinic of Neurorehabilitation and Paraplegiology, REHAB Basel, Basel, Switzerland
- 700 1_
- $a Saur, Marion $u Orthopädische Klinik, Hessisch Lichtenau, Germany
- 700 1_
- $a Benito, Jesús $u Fundacio Institut d'Investigacio en Ciencies de la Salut Germans Trias i Pujol, Barcelona, Spain
- 700 1_
- $a Rehahn, Kerstin $u Treatment Centre for Spinal Cord Injuries, Trauma Hospital Berlin, Berlin, Germany
- 700 1_
- $a Aach, Mirko $u Department of Spinal Cord Injuries, BG University Hospital Bergmannsheil, Bochum, Germany
- 700 1_
- $a Badke, Andreas $u BG Clinic Tübingen, Tübingen, Germany
- 700 1_
- $a Kriz, Jiri $u Spinal Cord Unit, Department of Rehabilitation and Sports Medicine, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic
- 700 1_
- $a Barkovits, Katalin $u Medical Proteome Analysis, Center for Proteindiagnostics (PRODI), Ruhr-University Bochum, Bochum, Germany
- 700 1_
- $a Killeen, Tim $u Spinal Cord Injury Center, Balgrist University Hospital, University of Zurich, Zurich, Switzerland
- 700 1_
- $a Farner, Lynn $u Spinal Cord Injury Center, Balgrist University Hospital, University of Zurich, Zurich, Switzerland
- 700 1_
- $a Seif, Maryam $u Spinal Cord Injury Center, Balgrist University Hospital, University of Zurich, Zurich, Switzerland
- 700 1_
- $a Hubli, Michèle $u Spinal Cord Injury Center, Balgrist University Hospital, University of Zurich, Zurich, Switzerland
- 700 1_
- $a Marcus, Katrin $u Medical Proteome Analysis, Center for Proteindiagnostics (PRODI), Ruhr-University Bochum, Bochum, Germany
- 700 1_
- $a Maurer, Michael A $u Institute for Regenerative Medicine, University of Zurich, Switzerland
- 700 1_
- $a Robert, Bérénice $u Clinical Study Coordination Center, University of Heidelberg, Heidelberg, Germany
- 700 1_
- $a Rupp, Rüdiger $u Spinal Cord Injury Center, Heidelberg University Hospital, Heidelberg, Germany
- 700 1_
- $a Scheuren, Paulina S $u Spinal Cord Injury Center, Balgrist University Hospital, University of Zurich, Zurich, Switzerland; International Collaboration on Repair Discoveries, University of British Columbia, Vancouver, BC, Canada
- 700 1_
- $a Schubert, Martin $u Spinal Cord Injury Center, Balgrist University Hospital, University of Zurich, Zurich, Switzerland
- 700 1_
- $a Schuld, Christian $u Spinal Cord Injury Center, Heidelberg University Hospital, Heidelberg, Germany
- 700 1_
- $a Sina, Christina $u Wyss Zurich Translational Center, University and ETH Zurich, Zurich, Switzerland
- 700 1_
- $a Steiner, Bettina $u Wyss Zurich Translational Center, University and ETH Zurich, Zurich, Switzerland
- 700 1_
- $a Weis, Tanja $u Department of Cardiology, Angiology and Pneumonology, Heidelberg University Hospital, Heidelberg, Germany; German Centre for Cardiovascular Research (DZHK), Partner Site Heidelberg/Mannheim, Heidelberg/Mannheim, Germany
- 700 1_
- $a Hug, Andreas $u Spinal Cord Injury Center, Heidelberg University Hospital, Heidelberg, Germany
- 700 1_
- $a Bolliger, Marc $u Spinal Cord Injury Center, Balgrist University Hospital, University of Zurich, Zurich, Switzerland
- 700 1_
- $a Weiskopf, Nikolaus $u Department of Neurophysics, Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany; Felix Bloch Institute for Solid State Physics, Faculty of Physics and Earth Sciences, Leipzig University, Leipzig, Germany; Wellcome Centre for Human Neuroimaging, Institute of Neurology, University College London, London, UK
- 700 1_
- $a Freund, Patrick $u Spinal Cord Injury Center, Balgrist University Hospital, University of Zurich, Zurich, Switzerland; Wellcome Centre for Human Neuroimaging, Institute of Neurology, University College London, London, UK
- 700 1_
- $a Hothorn, Torsten $u Epidemiology, Biostatistics, and Prevention Institute, University of Zurich, Switzerland
- 700 1_
- $a Schwab, Martin E $u Institute for Regenerative Medicine, University of Zurich, Switzerland; Wyss Zurich Translational Center, University and ETH Zurich, Zurich, Switzerland
- 700 1_
- $a Curt, Armin $u Spinal Cord Injury Center, Balgrist University Hospital, University of Zurich, Zurich, Switzerland
- 710 2_
- $a Nogo Inhibition in Spinal Cord Injury Study Group
- 773 0_
- $w MED00006921 $t Lancet neurology $x 1474-4465 $g Roč. 24, č. 1 (2025), s. 42-53
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39706632 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250121 $b ABA008
- 991 __
- $a 20250206103908 $b ABA008
- 999 __
- $a ok $b bmc $g 2262942 $s 1238855
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 24 $c 1 $d 42-53 $e - $i 1474-4465 $m Lancet neurology $n Lancet Neurol $x MED00006921
- LZP __
- $a Pubmed-20250121
